Press coverage about Ritter Pharmaceuticals (NASDAQ:RTTR) has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.7000504210295 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of analysts have recently issued reports on RTTR shares. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Chardan Capital lowered their price objective on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, August 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Ritter Pharmaceuticals has an average rating of “Buy” and a consensus target price of $2.92.
Ritter Pharmaceuticals (NASDAQ:RTTR) opened at $0.35 on Friday. Ritter Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.14). equities research analysts forecast that Ritter Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.